Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs Label Dosage of Humatrope in Early Pubertal Children with GHD
NCT00191165Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2004
- Primary completion
- Apr 2008
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Height Velocity Standard Deviation Score at 12 months. Started Mar 2004; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00191165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191165.